论文部分内容阅读
目的:探讨普伐他汀钠对糖尿病合并高脂血症的降脂治疗效果。方法:选择我院2009年1月至2011年12月糖尿病合并高脂血症患者75例。使用普伐他汀片20mgqd口服,12周为一个疗程,测定治疗前、治疗后4、12周患者血脂TC、TG、LDL-C等。同时给予胰岛素或磺脲类或者双胍类等降糖药控制血糖等。结果:治疗后4、12周后患者血脂TC、TG、LDL-C等和治疗前相比有明显降低(p<0.05),75例患者均未出现腹痛、便秘、胃肠胀气、疲乏无力和肌肉疼痛等现象。结论:普伐他汀钠能够限制改善糖尿病并发高脂血症患者的血脂,临床运用效果确切,不良反应少,值得临床推广应用。
Objective: To investigate the effect of pravastatin sodium on lipid-lowering therapy in diabetic patients with hyperlipidemia. Methods: From January 2009 to December 2011, 75 cases of diabetic patients with hyperlipidemia were selected. The use of pravastatin tablets 20mgqd oral, 12 weeks for a course of treatment before and after treatment, 4,12 weeks after treatment of patients with lipid TC, TG, LDL-C and so on. At the same time give insulin or sulfonylurea or biguanide hypoglycemic agents such as blood sugar control. Results: After 4 and 12 weeks of treatment, the levels of TC, TG, LDL-C and other factors were significantly lower than those before treatment (p <0.05). None of the 75 patients had abdominal pain, constipation, flatulence, Muscle pain and other phenomena. Conclusion: Pravastatin sodium can limit the improvement of blood lipids in patients with hyperlipidemia. The clinical effect of pravastatin sodium is definite and the adverse reactions are few, which is worthy of clinical application.